SF Healthcare Week: Beam's CEO John Evans shares an update on based editing for alpha-1 antitrypsin deficiency, sickle cell disease, and more
BiotechTV - News
00:00
Beam 302 and accelerated approval alignment
John Evans explains Beam 302 for alpha-1, RMAT designation, and FDA alignment on an accelerated approval pathway.
Play episode from 00:32
Transcript
